A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

A, Drilon; S, Fu; MR, Patel; M, Fakih; D, Wang; AJ, Olszanski; D, Morgensztern; SV, Liu; BC, Cho; L, Bazhenova; CP, Rodriguez; RC, Doebele; A, Wozniak; KL, Reckamp; T, Seery; P, Nikolinakos; Z, Hu; JW, Oliver; D, Trone; K, McArthur; R, Patel; PS, Multani; MJ, Ahn

doi:10.1158/2159-8290.cd-18-0839

Public

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Shared by NobleBlocks on Nov 28, 2018 • 12:00 AM UTC

Authors:

Drilon A

Fu S

Patel MR

Abstract

<i>RET</i> fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLC). The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial. A recommended phase II dose of 275 mg fed daily was identified. The most common ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!